查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1493357

美国发炎性肠道疾病治疗市场规模、份额、趋势分析报告：按类型、药物类别、给药途径、分销管道、地区、细分市场预测，2024-2030 年

U.S. Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report By Type, By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 70 Pages | 商品交期: 2-10个工作天内

价格

美国发炎性肠道疾病疾病治疗市场的成长与趋势：

Grand View Research, Inc.的最新报告显示，到2030年，美国发炎性肠道疾病治疗市场规模预计将达到141亿美元，2024年至2030年复合年增长率为2.5%。

预计美国各地溃疡性大肠炎和克隆氏症率的上升将推动预测期内的市场成长。发炎性肠道疾病（IBD）的发展被认为受到遗传倾向、免疫系统功能障碍、环境因素、肠道微生物群失衡和生活方式因素的综合影响。根据 2023 年发表的一篇论文，发炎性肠道疾病是一种相对常见的慢性疾病，影响超过 0.7% 的美国人，并且在东北部地区最受欢迎。越来越多的患者需要先进的治疗方案，以推动市场成长。

克隆氏症和结肠炎基金会致力于加强产品开发，以改善发炎性肠道疾病患者的生活品质。该基金会正在推出专用的资助系统 Venture，以支持以产品为导向的研究和开发。

2023年9月，武田宣布FDA已接受生技药品用于治疗克隆氏症的ENTYVIO（通用名：vedolizumab）皮下给药的生物製剂核准申请（BLA）。监管部门的核准为新药、生技药品和医疗设备进入市场铺平了道路。这可以扩大 IBD 患者的治疗选择并改善治疗结果和生活品质。

美国发炎性肠道疾病治疗市场报告亮点

  • 按类型划分，克隆氏症细分市场在 2023 年占据最大销售份额，占据市场主导地位。如此大的比例是由于克隆氏症的慢性发炎性质造成的，它会影响胃肠道并引起腹痛、腹泻、体重减轻和疲劳等症状，需要更多的治疗选择和进步。
  • 另一方面，由于溃疡性大肠炎的盛行率不断增加，预计在预测期内复合年增长率最快。
  • 按药物类别划分，TNF 抑制剂因其在控制症状和抑制发炎方面的有效性而在 2023 年占据最大的市场收入份额。
  • 以给药途径划分，注射剂在 2023 年占据最大的市场占有率。注射药物，例如生技药品和生物仿製药，旨在针对参与发炎性肠道疾病发炎过程的特定蛋白质和细胞。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章美国发炎性肠道疾病治疗市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 美国发炎性肠道疾病治疗市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章美国发炎性肠道疾病治疗市场：类型估计和趋势分析

  • 2023 年和 2030 年按类型分類的市场占有率
  • 细分仪表板
  • 美国发炎性肠道疾病治疗市场前景（按类型）
  • 2018-2030年市场规模、预测及趋势分析

第五章美国发炎性肠道疾病治疗市场：药物类别估计与趋势分析

  • 2023 年及 2030 年药品类别市场占有率
  • 细分仪表板
  • 美国发炎性肠道疾病治疗市场前景（依药物类别）
  • 2018-2030年市场规模、预测及趋势分析
  • 胺基
  • 皮质类固醇
  • 肿瘤坏死因子抑制剂
  • IL抑制剂
  • 抗整合素
  • JAK抑制剂

第六章美国发炎性肠道疾病治疗市场：给药途径预估及趋势分析

  • 2023 年及 2030 年给药途径市场占有率
  • 细分仪表板
  • 美国发炎性肠道疾病疾病治疗市场：按途径的前景
  • 2018-2030年市场规模、预测及趋势分析
  • 口服
  • 注射

第七章美国发炎性肠道疾病治疗市场：通路估算及趋势分析

  • 2023 年及 2030 年分销通路市场占有率
  • 细分仪表板
  • 美国发炎性肠道疾病疾病治疗市场：按分销管道分類的展望
  • 2018-2030年市场规模、预测及趋势分析
  • 医院药房
  • 零售药房
  • 网路药房

第八章美国发炎性肠道疾病治疗市场：区域估计和趋势分析

  • 2023 年和 2030 年按地区分類的市场占有率份额
  • 美国发炎性肠道疾病治疗市场：区域展望
  • 2018-2030年市场规模、预测及趋势分析
  • 西
  • 中西部
  • 东北
  • 西南
  • 东南

第9章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
  • 公司简介
    • Biogen
    • Novartis AG
    • Eli Lilly &Company
    • UCB SA
    • Celltrion Inc.
    • Merck &Co., Inc.
    • Johnson &Johnson Services, Inc.
Product Code: GVR-4-68040-286-7

U.S. Inflammatory Bowel Disease Treatment Market Growth & Trends:

The U.S. inflammatory bowel disease treatment market size is anticipated to reach USD 14.1 billion by 2030 and is projected to grow at a CAGR of 2.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of ulcerative colitis and Crohn's disease across the U.S. is anticipated to drive market growth in the forecast period. A combination of genetic predisposition, immune system dysfunction, environmental factors, gut microbiota imbalance, and lifestyle factors likely influence the development of inflammatory bowel disease (IBD). According to an article published in 2023, inflammatory bowel disease is a relatively common chronic condition affecting >0.7% of Americans and is most prevalent in the Northeastern region. This growing patient population necessitates advanced treatment options, driving the market growth.

The Crohn's & Colitis Foundation works toward enhancing product development to improve the quality of life of patients suffering from inflammatory bowel illnesses. The foundation has launched these ventures, a dedicated funding system to support product-oriented research and development.

In September 2023, Takeda announced the FDA's acceptance of the biologics license application (BLA) for the subcutaneous administration of ENTYVIO (vedolizumab) to treat Crohn's disease. Regulatory approvals pave the way for new medications, biologics, and devices to enter the market. This can lead to a broader range of treatment options for patients with IBD, potentially improving treatment outcomes and quality of life.

U.S. Inflammatory Bowel Disease Treatment Market Report Highlights:

  • Based on type, the Crohn's disease segment dominated the market in 2023 with the largest revenue share. This large share is due to the requirement for more treatment options and advancements due to the chronic inflammatory nature of Crohn's disease, which affects the gastrointestinal tract and causes symptoms such as abdominal pain, diarrhea, weight loss, and fatigue.
  • On the other hand, the ulcerative colitis segment is expected to register the fastest CAGR during the forecast period, owing to its increasing incidence rate.
  • Based on drug class, the TNF inhibitors segment accounted for the largest market revenue share in 2023 due to their effectiveness in managing the symptoms and reducing inflammation.
  • Based on route of administration, the injectable segment held the largest market share in 2023. Injectable medications, such as biologics and biosimilars, are designed to target specific proteins or cells involved in the inflammatory process of inflammatory bowel disease.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Drug Class
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution Channel
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type
    • 2.2.2. Drug Class
    • 2.2.3. Route of Administration
    • 2.2.4. Distribution Channel
  • 2.3. Competitive Insights

Chapter 3. U.S. Inflammatory Bowel Disease Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Inflammatory Bowel Disease Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Inflammatory Bowel Disease Treatment Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Inflammatory Bowel Disease Treatment Market by Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 4.4.1. Crohn's Disease
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.2. Ulcerative Colitis
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. U.S. Inflammatory Bowel Disease Treatment Market: Drug Class Estimates & Trend Analysis

  • 5.1. Drug Class Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Inflammatory Bowel Disease Treatment Market by Drug Class Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 5.4.1. Aminosalicylates
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.2. Corticosteroids
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.3. TNF Inhibitors
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.4. IL Inhibitors
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.5. Anti-integrin
      • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.6. JAK Inhibitors
      • 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.7. Others
      • 5.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. U.S. Inflammatory Bowel Disease Treatment Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Route of Administration Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. U.S. Inflammatory Bowel Disease Treatment Market by Route of Administration Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 6.4.1. Oral
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.2. Injectable
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. U.S. Inflammatory Bowel Disease Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Distribution Channel Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. U.S. Inflammatory Bowel Disease Treatment Market by Distribution Channel Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 7.4.1. Hospital Pharmacy
      • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.2. Retail Pharmacy
      • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.3. Online Pharmacy
      • 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 8. U.S. Inflammatory Bowel Disease Treatment Market: Region Estimates & Trend Analysis

  • 8.1. Regional Market Share, 2023 & 2030
  • 8.2. U.S. Inflammatory Bowel Disease Treatment Market by Region Outlook
  • 8.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 8.3.1. West
      • 8.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 8.3.2. Midwest
      • 8.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.3. Northeast
      • 8.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.4. Southwest
      • 8.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.5. Southeast
      • 8.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company heat map analysis, 2023
  • 9.4. Company Profiles
    • 9.4.1. Biogen
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. Novartis AG
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. Eli Lilly & Company
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. UCB S.A.
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. Celltrion Inc.
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. Merck & Co., Inc.
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Johnson & Johnson Services, Inc.
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. inflammatory bowel disease treatment market, by type, 2018 - 2030 (USD Million)
  • Table 3 U.S. inflammatory bowel disease treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 4 U.S. inflammatory bowel disease treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 U.S. inflammatory bowel disease treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 U.S. inflammatory bowel disease treatment market, by region, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. inflammatory bowel disease treatment market: market outlook
  • Fig. 9 U.S. Inflammatory bowel disease treatment competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 U.S. inflammatory bowel disease treatment market driver impact
  • Fig. 14 U.S. inflammatory bowel disease treatment market restraint impact
  • Fig. 15 U.S. inflammatory bowel disease treatment market: Type movement analysis
  • Fig. 16 U.S. inflammatory bowel disease treatment market: Type outlook and key takeaways
  • Fig. 17 Crohn's Disease market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Ulcerative Colitis estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 U.S. inflammatory bowel disease treatment market: Drug class movement analysis
  • Fig. 20 U.S. inflammatory bowel disease treatment market: Drug class outlook and key takeaways
  • Fig. 21 Aminosalicylates market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Corticosteroids market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 TNF inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 IL inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Anti-integrin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 JAK inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. inflammatory bowel disease treatment market: Route of administration movement analysis
  • Fig. 28 U.S. inflammatory bowel disease treatment market: Route of administration outlook and key takeaways
  • Fig. 29 Oral market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Injectable market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. inflammatory bowel disease treatment market: Distribution channel movement analysis
  • Fig. 32 U.S. inflammatory bowel disease treatment market: Distribution channel outlook and key takeaways
  • Fig. 33 Hospital pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Retail pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Online pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. inflammatory bowel disease treatment market: Regional movement analysis
  • Fig. 37 U.S. inflammatory bowel disease treatment market: Regional outlook and key takeaways
  • Fig. 38 West market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)